[1]姬颖华,杨晓煜,孟祥丽,等.盐酸安罗替尼联合信迪利单抗治疗标准治疗失败后微卫星稳定型结直肠癌疗效观察[J].新乡医学院学报,2021,38(8):719-724.[doi:10.7683/xxyxyxb.2021.08.004]
　JI Yinghua,YANG Xiaoyu,MENG Xiangli,et al.Clinical efficacy of Anlotinib hydrochloride combined with Sintilimab in the treatment of microsatellite stable colorectal cancer after the failure of standard treatment[J].Journal of Xinxiang Medical University,2021,38(8):719-724.[doi:10.7683/xxyxyxb.2021.08.004]
点击复制

盐酸安罗替尼联合信迪利单抗治疗标准治疗失败后微卫星稳定型结直肠癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年8
页码:
719-724
栏目:
临床研究
出版日期:
2021-08-05

文章信息/Info

Title:
Clinical efficacy of Anlotinib hydrochloride combined with Sintilimab in the treatment of microsatellite stable colorectal cancer after the failure of standard treatment
作者:
姬颖华1; 杨晓煜2; 孟祥丽1; 谢晋玲1; 王　瑾1; 张　敏1; 杨留中1; 路　平1; 张景航3
（1.新乡医学院第一附属医院肿瘤科,河南　卫辉　453100；2.新乡医学院基础医学院病理学教研室，河南　新乡　453003；3.新乡医学院第一附属医院病理科，河南　卫辉　453100）
Author(s):
JI Yinghua1; YANG Xiaoyu2; MENG Xiangli1; XIE Jinling1; WANG Jin1; ZHANG Min1; YANG Liuzhong1; LU Ping1; ZHANG Jinghang3
（1.Depatment of Oncology,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100，Henan Province,China；2.Department of Pathology,School of Basic Medicine of Xinxiang Medical University,Xinxiang 453003，Henan Province，China；3.Department of Pathology,the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，Henan Province，China）
关键词:
微卫星稳定型; 结直肠癌; 盐酸安罗替尼; 信迪利单抗
Keywords:
microsatellite stablecolorectal cancerAnlotinib hydrochlorideSintilimab
分类号:
R735.3+7
DOI:
10.7683/xxyxyxb.2021.08.004
文献标志码:
A
摘要:
目的　探讨盐酸安罗替尼联合信迪利单抗治疗标准治疗失败后微卫星稳定（MSS）型结直肠癌患者的临床疗效及安全性。方法　选择2019年5月至2020年2月新乡医学院第一附属医院收治的36例MSS型结直肠癌患者为研究对象，根据治疗方式将患者分为对照组（n=17）和观察组（n=19）。对照组患者给予盐酸安罗替尼胶囊口服治疗，每日1 次，每次10 mg，连续给药2周后停用1周，第2次调整剂量为12 mg，连续给药2周后停用1周，共治疗6个月。观察组患者在对照组治疗基础上给予信迪利单抗注射液静脉输注治疗，每次200 mg，每3周给药1次，共治疗6个月。治疗6个月后，使用实体瘤疗效评定标准1.1 版评价临床疗效，包括完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）、疾病进展（PD），计算客观缓解率（ORR）和疾病控制率（DCR）。应用肿瘤病人生活质量评分评估患者生活质量，使用常见不良反应事件评价标准4.0 评价药物不良反应。比较2组患者的临床疗效、生活质量及不良反应。结果　对照组患者的ORR为5.88%，DCR为35.29%；观察组患者的ORR为15.79%，DCR为52.63%。2组患者的ORR及DCR比较差异无统计学意义（P>0.05）。治疗前，2组患者5个功能子量表及总体生命质量评分比较差异均无统计学意义（P>0.05）。2组患者治疗6个月后躯体功能、情绪功能、总体生命质量评分显著高于治疗前（P<0.05）；治疗6个月后，观察组患者躯体功能、情绪功能、总体生命质量评分显著高于对照组（P<0.05），观察组患者角色功能、认知功能、社会功能评分与对照组比较差异无统计学意义（P>0.05）。2组患者治疗前症状子量表评分比较差异无统计学意义（P>0.05）；治疗6个后，2组患者疲乏评分高于治疗前，疼痛评分显著低于治疗前（P<0.05）；2组患者恶心呕吐评分与治疗前比较差异无统计学意义（P>0.05）。治疗6个月后，观察组患者疼痛评分低于对照组（P<0.05），2组患者疲乏评分及恶心呕吐评分比较差异均无统计学意义（P>0.05）。2组患者治疗6个月后呼吸困难评分、失眠评分及食欲丧失评分显著低于治疗前（P<0.05），2组患者便秘、腹泻、经济影响评分与治疗前比较差异均无统计学意义（P>0.05）。治疗6个月后，观察组患者呼吸困难评分、失眠评分显著低于对照组，食欲丧失评分显著高于对照组（P<0.05）；观察组与对照组患者治疗后便秘评分、腹泻评分、经济影响评分比较差异无统计学意义（P>0.05）。对照组患者不良反应发生率为64.17%（11/17），观察组患者不良反应发生率为68.42%（13/19）；对照组与观察组患者不良反应发生率比较差异无统计学意义（χ2=0.056，P>0.05）。结论　盐酸安罗替尼联合信迪利单抗治疗标准治疗失败后MSS型结直肠癌患者的临床疗效较好，可有效缓解临床症状，改善患者生命质量，且不良反应可控。
Abstract:
Objective　To investigate the clinical efficacy and safety of Anlotinib hydrochloride combined with Sintilimab in the treatment of microsatellite stable (MSS) colorectal cancer after the failure of standard treatment.Methods　A total of 36 patients with MSS colorectal cancer admitted to the First Affiliated Hospital of Xinxiang Medical University from May 2019 to February 2020 were selected as the research subjects,and they were divided into control group (n=17) and observation group (n=19) according to different treatment methods.The patients in the control group were given Anlotinib hydrochloride capsules orally,once a day,10 mg each time,continuously administrated for two weeks and then stopped for one week,the second dose was adjusted to 12 mg,the treatment lasted for six months.The patients in the observation group were given sintilimab injection intravenously on the basis of the treatment of patients in the control group,200 mg each time,once every three weeks,continuously administrated for two weeks and then stopped for one week,the treatment lasted for six months.After six months of treatment,version 1.1 of the evaluation criteria for the efficacy of solid tumors was used to evaluate the clinical efficacy,including complete remission (CR),partial remission (PR),stable disease (SD),and disease progression (PD).The objective response rate (ORR) and disease control rate (DCR) were calculated.The quality of life score of cancer patients was used to assess the patient′s quality of life,and the 4.0 standard for evaluation of common adverse events was used to evaluate adverse drug reactions.The clinical efficacy,quality of life and adverse reactions of patients between the two groups were compared.Results　The ORR,DCR of patients in the control group was 5.88%,35.29%,respectively.The ORR,DCR of patients in the observation group was 15.79%,52.63%,respectively.There was no significant difference in ORR and DCR of patients between the two groups (P>0.05).Before treatment,there was no statistically significant difference in the five functional subscales and overall quality of life scores of the patients between the two groups (P>0.05).The scores of physical function,emotional function and overall quality of life of the patients in the two groups after six months of treatment were significantly higher than those before treatment (P<0.05)after six months of treatment,the scores of physical function,emotional function and overall quality of life of the patients in the observation group were significantly higher than those in the control group (P<0.05).There was no significant differences in the role function,cognitive function and social function scores of the patients between the two groups after six months of treatment (P>0.05).There was no significant difference in the scores of the symptom subscale between the two groups before treatment (P>0.05).After six months of treatment,the fatigue score of the patients in the two groups was significantly higher than that before treatment,and the pain score of the patients was significantly lower than that before treatment (P<0.05).There was no significant difference in the nausea score and vomiting score of patients after six months of treatment compared with those before treatment in the two groups (P>0.05).After six months of treatment,the pain score of the patients in the observation group was significantly lower than that in the control group (P<0.05)and there was no significant difference in fatigue score and nausea and vomiting score of the patients between the two groups (P>0.05).The dyspnea score,insomnia score of the patients after six months of treatment were significantly lower than those before treatment,and the loss of appetite score was significantly higher than that before treatment in the two groups (P<0.05)after six months of treatment,the dyspnea score,insomnia score and loss of appetite score of patients in the observation group were significantly lower than those in the control group (P<0.05)there was no significant difference in constipation score,diarrhea score and economic impact score of patients between the two groups (P>0.05).The incidence of adverse drug reactions in the control group was 64.17% (11/17),and the incidence of adverse drug reactions in the observation group was 68.42% (13/19)there was no significant difference in the incidence of adverse drug reactions between the control group and observation group (χ2=0.056,P>0.05).Conclusion　Anlotinib hydrochloride combined with Sintilimab in the treatment of patients with MSS colorectal cancer after the failure of standard treatment has better clinical efficacy,which can effectively relieve clinical symptoms,improve the quality of life of patients,and the adverse drug reactions can be controlled.

参考文献/References:

［1］　南鹏,李春晓,孙芳洲,等.食管癌化疗耐药相关基因的初步筛选及其临床意义［J］.解放军医学杂志,2019,44(3)：222-227.
［2］　邓洁,董丽丽,杨茂鹏,等.阿帕替尼联合GP方案化学治疗晚期肺癌患者的近期临床效果及对血清肿瘤标志物的影响［J］.临床误诊误治,2018,31(8):66-69.
［3］　许芳,赵阳,武其文.高通量测序技术在检测循环肿瘤细胞中的应用［J］.分子诊断与治疗杂志,2018,10(1):56-60,72.
［4］　侯新芳,李帅,吴晨,等.儿童及青少年消化道恶性实体瘤临床分析［J］.中华实用儿科临床杂志,2018,33(12):928-932.
［5］　NATIONAL INSTITUTE HEALTH (NIH),NATIONAL CANCEＲINSTITUTE.Common Terminology Criteria for Adverse Events(CTCAE) Version 4.0［EB/OL］.Maryland: NIH.2009-05-28［2016-10-22］.https://web.emmes.com/study/bmt2/public/Definition/CTCAE_4_03_2010 -06-14.Pdf.
［6］　夏铮铮,孟珺,冯立.肿瘤患者化疗后粒细胞集落刺激因子的使用情况分析［J］.保健医学研究与实践,2019,16(2):57-59,65.
［7］　陈玥,莫泽明,秦笛源,等.靶向ROR1的嵌合抗原受体修饰T细胞的构建及对ROR1阳性肿瘤细胞的杀伤作用［J］.四川大学学报(医学版),2019,50(2)：145-151.
［8］　AZIZOVA A N,TAGIEV D B,OSMANOVA S N,et al.Crystal and molecular structure of a platinum(II) complex with β-mercapto-ethylamine hydrochloride［J］.Chin J Struct Chem,2018,59(1):188-192.
［9］　邹宜覃,宁方政,张景熙,等.盐酸安罗替尼治疗晚期非小细胞肺癌临床疗效及影响因素分析［J］.国际呼吸杂志,2020,40(7):493-498.
［10］　KANG S,NA Y,JOUNG S Y,et al.The significance of microsa-tellite instability in colorectal cancer after controlling for clinicopathological factors［J］.Medicine(Baltimore),2018,97(9):e0019.
［11］　李娜,黄琦,张明军,等.安罗替尼三线治疗晚期转移性结直肠癌疗效分析［J］.中华医学杂志,2019,99(36):2844-2847.
［12］　王亚梦,孟宇,师霄楠,等.盐酸安罗替尼治疗晚期原发性肝癌的临床疗效、安全性及预后分析［J］.中华肝脏病杂志,2020,28(7):619-624.
［13］　HUSSAR D A,MOYER M R.Baloxavir marboxil,fremanezumab-vfrm,galcanezumab-gnlm,and lofexidine hydrochloride［J］.J Am Pharm Assoc,2019,59(1):141-144.
［14］　韩骐蔓,侯和磊,张晓春.国产创新药安罗替尼抗肿瘤治疗的研究进展［J］.中国新药与临床杂志,2020,25(2):65-70.
［15］　AZIZOVA A N,TAGIEV D B,OSMANOVA S N,et al.Crystal and molecular structure of a platinum(II) complex with β-mercaptoethylamine hydrochloride［J］.J Struct Chem,2018,59(1)：188-192.
［16］　朱丹,李月阳,宋燕青,等.PD-1抑制剂信迪利单抗的临床研究进展［J］.中国医院药学杂志,2020,40(1):120-123.
［17］　庄荣源,王志明,郭曦,等.安罗替尼联合化疗治疗晚期软组织肉瘤的近期疗效及安全性分析［J］.中国临床医学,2019,26(3)：378-381.
［18］　AGRAWAL S,GURJAR P,KATHERIYA B.Analytical method development and validation for simultaneous estimation of trimetazidine hydrochloride and metoprolol succinate using HPTLC［J］.Curr Pharm Anal,2019,15(3):243-250.
［19］　胡德升,高磊,王江,等.外周血胸苷酸合成酶基因表达与中晚期结直肠癌患者FOLFOX4化学治疗敏感性和预后的相关性［J］.新乡医学院学报,2020,37(10):930-934.
［20］　杨雪晶,宋东,杨晓玲,等.盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性分析［J］.肿瘤研究与临床,2020,32(7):489-492.

相似文献/References:

[1]朱武凌 范秉琳.青年与老年结直肠癌C—erbB一2不同表达与DNA倍体的关系[J].新乡医学院学报,2002,19(03):170.
[2]王璧,王战会,韩保卫,等.Runt相关转录因子3在结直肠癌组织中的表达及意义[J].新乡医学院学报,2022,39(12):1127.[doi:10.7683/xxyxyxb.2022.12.005]
　WANG Bi,WANG Zhanhui,HAN Baowei,et al.Expression and significance of Runt-related transcription factor 3 in colorectal cancer[J].Journal of Xinxiang Medical University,2022,39(8):1127.[doi:10.7683/xxyxyxb.2022.12.005]
[3]齐光照,李朵璐.细胞色素P450酶CYP2W1研究进展[J].新乡医学院学报,2019,36(7):698.[doi:10.7683/xxyxyxb.2019.07.025]
[4]李怡春,张　敏,杨晓煜,等.CD133在人结直肠癌组织中的表达及其与缺氧诱导因子1α和核心蛋白聚糖的相关性[J].新乡医学院学报,2019,36(11):1036.[doi:10.7683/xxyxyxb.2019.11.007]
　LI Yi-chun,ZHANG Min,YANG Xiao-yu,et al.Expression of CD133 in human colorectal cancer tissues and correlation with hypoxia-induced factor-1α and decorin[J].Journal of Xinxiang Medical University,2019,36(8):1036.[doi:10.7683/xxyxyxb.2019.11.007]
[5]平贯芳,熊万成,邓智建.长链非编码RNA 浆细胞瘤转化迁移基因1在结直肠癌组织和细胞中的表达及临床意义[J].新乡医学院学报,2019,36(10):949.[doi:10.7683/xxyxyxb.2019.10.011]
　PING Guan-fang,XIONG Wan-cheng,DENG Zhi-jian.Expression and clinical significance of long-chain non-coding RNA plasmacytoma variant translocation gene 1 in colorectal cancer tissues and cells[J].Journal of Xinxiang Medical University,2019,36(8):949.[doi:10.7683/xxyxyxb.2019.10.011]
[6]吕文豪,董　媛,魏子白.二甲双胍在结直肠癌治疗中的作用研究进展[J].新乡医学院学报,2021,38(7):692.[doi:10.7683/xxyxyxb.2021.07.020]
[7]马　晓,陈国荣,李君艳,等.外周血中性粒细胞与淋巴细胞比值及血清癌胚抗原、糖类抗原199联合检测对结直肠癌的诊断价值[J].新乡医学院学报,2021,38(1):062.[doi:10.7683/xxyxyxb.2021.01.013]
　MA Xiao,CHEN Guorong,LI Junyan,et al.Value of combined detection of neutrophil-lymphocyte ratio in peripheral blood,serum carcinoembryonic antigen and carbohydrate antigen 199 in the diagnosis of colorectal cancer[J].Journal of Xinxiang Medical University,2021,38(8):062.[doi:10.7683/xxyxyxb.2021.01.013]
[8]谢　阳,赵李红,杨昌建,等.不同肺复张策略治疗腹腔镜下结直肠癌根治术患者围手术期肺不张疗效观察[J].新乡医学院学报,2021,38(9):857.[doi:10.7683/xxyxyxb.2021.09.012]
　XIE Yang,ZHAO Lihong,YANG Changjian,et al.Effect of different lung recruitment strategies in treatment of perioperative atelectasis of patients undergoing laparoscopic radical resection of colorectal cancer[J].Journal of Xinxiang Medical University,2021,38(8):857.[doi:10.7683/xxyxyxb.2021.09.012]
[9]胡德升,高　磊,王　江,等.外周血胸苷酸合成酶基因表达与中晚期结直肠癌患者FOLFOX4化学治疗敏感性和预后的相关性[J].新乡医学院学报,2020,37(10):930.[doi:10.7683/xxyxyxb.2020.10.007]
　HU Desheng,GAO Lei,WANG Jiang,et al.Correlation between thymidylate synthase gene expression in peripheral blood and FOLFOX4 chemotherapy sensitivity and prognosis of patients with advanced colorectal cancer[J].Journal of Xinxiang Medical University,2020,37(8):930.[doi:10.7683/xxyxyxb.2020.10.007]
[10]王　鑫,王　钊,李元春,等.热休克蛋白70及基质金属蛋白酶-7和EHD2蛋白在结直肠癌组织中的表达及意义[J].新乡医学院学报,2019,36(5):443.[doi:10.7683/xxyxyxb.2019.05.010]
　WANG Xin,WANG Zhao,LI Yuan-chun,et al.Expression and significance of heat shock protein 70，matrix metalloproteinase-7 and EHD2 in colorectal cancer tissues[J].Journal of Xinxiang Medical University,2019,36(8):443.[doi:10.7683/xxyxyxb.2019.05.010]

更新日期/Last Update: 2021-08-05